Since both rapamycin and carboplatin have demonstrated activity in canine melanoma cells and patients, respectively, as single agents, the goal of this study was to evaluate the combined effect of mTOR small molecule inhibitors with carboplatin. The gene discussed is MTOR; the disease is melanoma.